Mariner
ALLO icon

Mariner’s Allogene Therapeutics ALLO Stock Holding History

Mariner’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$265K Buy
108,722
+72,229
+198% +$145K ﹤0.01% 2978
2025
Q4 		$49.5K Sell
36,493
-177
-0.5% -$233 ﹤0.01% 3415
2025
Q3 		$45.5K Buy
+36,670
New +$43.7K ﹤0.01% 3458

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mariner's ALLO Position: Q1 2026 in Review

Mariner increased its Allogene Therapeutics (ALLO) stake by 198% in Q1 2026, buying an estimated $145K and bringing the position to 108,722 shares worth $265K. The position accounts for ﹤0.01% of the portfolio, ranked #2978.

Mariner first reported a position in ALLO in Q3 2025 and has held it in 3 quarters since. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Mariner held 108,722 shares of Allogene Therapeutics worth $265K as of Q1 2026.
  • Mariner bought 72,229 Allogene Therapeutics shares in Q1 2026, an estimated $145K.
  • Allogene Therapeutics made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #2978 holding.
  • Mariner first reported a position in Allogene Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.